
2007 INDEX FOR DA SB 8-75-S7

PARAGRAPH SUBJECT	SB 8-75-	PAGE
Acquisition Advice Codes and Unit-Funded Requisitions	S7	5-10
Additional Information [at the end of each chapter]	S7	
Additional Product Information – CBRN and MCDM	S7	5-4
APS and SC VIII APS Locations	S7	3-1
APS Program Background	S7	3-1
APS Storage Sites	S7	8-2
Army Prepositioned Stock (APS) Program	S7	3-1
Army Prepositioned Stock (APS), Reserve Component Hospital Decrement (RCHD), and Unit Deployment Package (UPD) Automated Systems	S7	8-1
Army War Reserve Deployment System (AWRDS)	S7	8-1
Asset Visibility	S7	8-2
Background – APS, RCHD, and UPD	S7	8-1
Background on DOD/FDA Shelf Life Extension Program (SLEP)	S7	9-1
Background on RCHD	S7	6-1
Class VIII Contingency Materiel Programs - Introduction	S7	1-1
Defense Medical Logistics Standard Support (DMLSS) System	S7	8-2
Destruction of MCDM	S7	5-9
DFP Components- Individual Service Member (Table 5-1)	S7	5-2
DFP Components- Individual Service Member (Table 5-1)	S7	5-2
DFP Components- Military Working Dog (Table 5-2)	S7	5-3
DFP Locations (Table 5-3)	S7	5-3
DH1 Project – Deployable Force Package (DFP)	S7	5-1
DH5 Project – Initial Potency & Dated (P&D) MCDM for the Medical Equipment Set, Chemical Agent Patient Treatment (LIN M23673)	S7	5-5
DOD/FDA Shelf Life Extension Program (SLEP)	S7	9-1
Emergency Operations Center (EOC), The Medical Logistics Support Team (MLST), and The USAMMA Forward Logistics Support Element (USAMMA FWD)	S7	7-1
FDA/DOD Shelf Life Extension Program Testing Criteria	S7	9-1
General Information (RCHD)	S7	6-2
Glossary for SB 8-75-S7	S7	GL-1
Initial Issue Medical, Chemical, Biological, Radiological, and Nuclear Defense Materiel (MCDM) - Introduction To	S7	5-1
Initial Issue P&D MCDM Locations (Table 5-5)	S7	5-6
International Logistics Office (ILO) and Foreign Military Sales (FMS)	S7	10-1
Introduction To Class VIII Contingency Materiel	S7	1-1
Labeling Requirements and Guidance	S7	9-4
Management and Accountability for Initial Issue Potency & Dated (P&D) MCDM for the Medical Equipment Set, Chemical Agent Patient Treatment (LIN M23673)	S7	5-7
Management and Accountability of Initial Issue DFP MCDM	S7	5-3
MLST Organizational Structure (Diagram)	S7	7-3

PARAGRAPH SUBJECT	SB 8-75-	PAGE
P&Ds for MES, Chemical Agent, Patient Treatment, LIN M23673 (Table 5-4)	S7	5-6
Procurement Strategies (UDPs)	S7	4-2
Program Composition for RCHD	S7	6-1
RCHD Background Information	S7	6-1
Relabeling of MCDM	S7	5-9
Release Authority (Deployments) (UDPs)	S7	4-3
Release Authority (Humanitarian Relief Only) (UDPs)	S7	4-3
Release Procedures for All Initial Issue MCDM	S7	5-7
Requirements Determination	S7	2-1
Reserve Component Hospital Decrement (RCHD)	S7	6-1
SC VIII APS Assets	S7	3-2
Shelf Life Extension Program Categories for Amy Materiel (Table 9-1)	S7	9-3
SLEP Process	S7	9-2
Storage Requirements (MCDM)	S7	5-8
Supply Class VIII Sustainment Requirements Process	S7	A-1
Testing Criteria (SLEP)	S7	9-1
The Army Centrally Managed Medical Potency and Dated (P&D) Materiel Program	S7	4-1
The USAMMA Forward Logistics Support Element (USAMMA FWD)	S7	7-3
The USAMMA Medical Logistics Support Team (MLST)	S7	7-1
Unit Level Logistics Systems-Ground (ULLS-G)	S7	8-3
War Reserve Requirements	S7	2-1
Website Information On DOD/FDA Shelf Life Extension Program (SLEP)	S7	9-4